Under construction – not a live service
Sign in
Taking people in United StatesNo phase

Tests a phone app for recording food intake in people with amyloidosis

Tests a phone app for food logging in adults with amyloidosis.

Plain-language title generated from the registry record
Registry title: Dietary Reporting In The Amyloidoses

Key facts

Where
Detroit, United StatesSee the site

Where in United States

  • Karmanos Cancer InstituteDetroit, United StatesTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Barbara Ann Karmanos Cancer Institute
Trial code
NCT05738005
Record updated
26 June 2026
Original description
The goal of this clinical trial is to learn about malnutrition and weight loss in patients with Amyloidosis.Read full original descriptionShow less

DRITA Pilot Trial: Dietary Reporting in the Amyloidoses

The goal of this clinical trial is to learn about malnutrition and weight loss in patients with Amyloidosis.

The main question it aims to answer is:

Is it feasible to use a low-cost nutrition-based application (apps) for use on a smartphone to obtain detailed information on caloric intake in Amyloidosis patients

Participants will be asked to:

* Download the MyFitnessPal application on their smartphone and view an online tutorial * After a week of practice, from weeks 2-9, participants will enter daily dietary intake as well as daily herbal/alternative supplement intake into the MyFitnessPal application on their smartphone. * complete a questionnaire prior to starting the application, after week 2 and at week 10 after starting the application

Inclusion: 18 years of age or older; Diagnosed with any type of amyloidosis; Speak, read and write in English; Willing to use the MyFitnessPal app on their own smartphone.

Exclusion: a planned autologous stem cell transplant or a solid organ transplant in the 12 weeks after enrollment; cognitive or perceptual disturbances.

ClinicalTrials.gov NCT05738005